Search
for
Sort by
Research 931–960 of 1000+
- Frontal fibrosing alopecia: a disease fascinating for the researcher, disappointing for the clinician and distressing for the patient
- Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
- Genes and Immune Response in Alopecia Areata: Review of the Alopecia Areata Research Summit First Day Proceedings
- Global burden of alopecia areata from 1990 to 2019 and emerging treatment trends analyzed through GBD 2019 and bibliometric data
- Management of folliculitis decalvans: The EADV task force on hair diseases position statement
- Pathophysiology of Alopecia Areata in the Pediatric Patient
- Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- Refractory alopecia in lupus treated with tofacitinib — a case-based review
- Acne exacerbation after tofacitinib treatment for alopecia areata
- Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
- Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
- Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- What’s New in Hair Loss
- Integrated single-cell chromatin and transcriptomic analyses of peripheral immune cells in patients with alopecia areata
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Biologics in the management of childhood atopic dermatitis
- Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review
- Hypohidrotic Ectodermal Dysplasia with c.28delG Mutation in Ectodysplasin A Gene and Severe Atopic Dermatitis Treated Successfully with Tofacitinib
- A Potential Role for IL-4 and IL-13 in an Alopecia Areata–Like Phenotype: A Clinical Perspective
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- TREMendous Macrophages Inhibit Hair Growth
- Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- The Importance of Readability: A Guide to Understanding Alopecia Areata through Multilingual Online Resources